Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Filament Health Corp FLHLF

Healthcare Biotechnology
Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Company’s platform of intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of Psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral... see more

Recent & Breaking News (GREY:FLHLF)

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca

ACCESS Newswire 8 days ago

FILAMENT HEALTH ANNOUNCES FDA AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING PSILOCYBIN FOR ALCOHOL USE DISORDER AND POST-TRAUMATIC STRESS DISORDER IN VETERANS AND FIRST RESPONDERS

Canada NewsWire 9 days ago

FILAMENT HEALTH ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF ALABAMA AT BIRMINGHAM FOR DATA FROM A CLINICAL TRIAL OF PSILOCYBIN FOR THE TREATMENT OF COCAINE USE DISORDER

Canada NewsWire June 17, 2025

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER

Canada NewsWire June 11, 2025

FILAMENT HEALTH ANNOUNCES TRANSITION FROM OTCQB TO OTC PINK LIMITED

Canada NewsWire May 27, 2025

FILAMENT HEALTH ANNOUNCES VOLUNTARY DELISTING FROM CBOE CANADA

Canada NewsWire May 19, 2025

FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire May 8, 2025

FILAMENT HEALTH ANNOUNCES FDA AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING PEX010, THE COMPANY'S BOTANICAL PSILOCYBIN DRUG CANDIDATE, IN OPIOID USE DISORDER

Canada NewsWire April 9, 2025

FILAMENT HEALTH ANNOUNCES PRIVATE PLACEMENT AND INTENTION TO VOLUNTARILY DELIST FROM CBOE CANADA

Canada NewsWire April 3, 2025

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire April 1, 2025

FILAMENT HEALTH ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY OF PEX010 IN PATIENTS WITH ALCOHOL USE DISORDER

Canada NewsWire March 17, 2025

FILAMENT HEALTH ANNOUNCES SHIPMENT OF BOTANICAL PSILOCYBIN TO THE UNIVERSITY OF WISCONSIN-MADISON

Canada NewsWire January 21, 2025

FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES

Canada NewsWire December 16, 2024

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire November 14, 2024

FILAMENT HEALTH ANNOUNCES ISSUANCE OF COMMON SHARES TO NEGEV CAPITAL INVESTMENTS LIMITED PURSUANT TO ADVISORY AGREEMENT

Canada NewsWire October 4, 2024

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire August 14, 2024

FILAMENT HEALTH ANNOUNCES MAJOR INTELLECTUAL PROPERTY EXPANSION

Canada NewsWire August 13, 2024

Negev Capital Fund One, L.P. Reports Updated Holdings in Filament Health Corp.

Newsfile June 14, 2024

FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES

Canada NewsWire June 12, 2024

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER

Canada NewsWire June 3, 2024